Publications
586
Citations
8,339
Est. group size
—
Recurring co-author estimate
Active years
35
Publishing since 1992
Leon Kircik conducts clinical research in dermatology, focusing on the treatment of common skin conditions such as acne, psoriasis, and atopic dermatitis (eczema). Much of the work involves testing the safety and effectiveness of topical creams, foams, gels, and oral medications through clinical trials, often examining outcomes across different patient groups and skin types.
Publication activity grew substantially over the last decade, rising from roughly 15 papers in 2017 to a peak of over 75 in 2023-2024, and remaining high in recent years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- 75516 Long-Term Efficacy and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% (CAB) Gel for Acne in Participants With Fitzpatrick Skin Phototypes IV-VI: Pooled Results From Two 6-Month Studies
Journal of the American Academy of Dermatology · 2026
- Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
The Lancet · 2025
- Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body
JAMA Dermatology · 2025
- Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis
Journal of the American Academy of Dermatology · 2025
- Defining On-Treatment Remission in Plaque Psoriasis
JAMA Dermatology · 2025
- Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations in Combating Rising Resistance in Cutibacterium acnes
Clinical Cosmetic and Investigational Dermatology · 2025
- Recommendations to Improve Outcomes in Acne and Acne Sequelae: A Focus on Trifarotene and Other Retinoids
Dermatology and Therapy · 2025
- Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks
American Journal of Clinical Dermatology · 2025
- Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
Journal of Dermatological Treatment · 2025
- Efficacy and safety of rilzabrutinib in patients with moderate-to-severe atopic dermatitis: 16-week results from a proof-of-concept phase II clinical trial
British Journal of Dermatology · 2025
- INDIVIDUAL ARTICLE: Appraisal of Ruxolitinib 1.5% Cream as a First-Line Topical Therapeutic Agent for Adolescents and Adults With Mild-to-Moderate Atopic Dermatitis
Journal of Drugs in Dermatology · 2025
- Tapinarof Cream for Adults and Children with Atopic Dermatitis—Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials
Dermatology and Therapy · 2025
- INDIVIDUAL ARTICLE: The Dark Side of Oral Antibiotics: Adverse Events of Consideration in Dermatology
Journal of Drugs in Dermatology · 2025
- INDIVIDUAL ARTICLE: Tirbanibulin 1% Ointment: Clinical Trial and Real-World Evidence on Efficacy, Tolerability, Safety, and Patient-Reported Outcomes
Journal of Drugs in Dermatology · 2025
- Safety and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Truncal Acne
Journal of Drugs in Dermatology · 2025
- SKIN The Journal of Cutaneous Medicine×127
- PubMed×114
- Journal of Drugs in Dermatology×71
- Journal of the American Academy of Dermatology×68
- Dermatology and Therapy×11
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile